BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 1698185)

  • 1. [Results of a randomized polychemotherapy study in malignant melanoma].
    Fiedler H; Hetschko I; Wohlrab W; Wozniak KD; Lübbe D; Taube KM
    Hautarzt; 1990 Jul; 41(7):369-74. PubMed ID: 1698185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Long-term results of adjuvant chemotherapy after therapeutic lymph node dissection in patients with cutaneous malignant melanoma].
    Kretschmer L; Helmbold P; Emmert S; Marsch WC
    Hautarzt; 2002 Aug; 53(8):536-41. PubMed ID: 12221468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy of disseminated melanoma with bleomycin, vincristine, CCNU, and DTIC (BOLD regimen). The Prudente Foundation Melanoma Study Group.
    Cancer; 1989 May; 63(9):1676-80. PubMed ID: 2467736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.
    Serrone L; Zeuli M; Sega FM; Cognetti F
    J Exp Clin Cancer Res; 2000 Mar; 19(1):21-34. PubMed ID: 10840932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete remission of brain metastases in three patients with stage IV melanoma treated with BOLD and G-CSF.
    Bottoni U; Bonaccorsi P; Devirgiliis V; Panasiti V; Borroni RG; Trasimeni G; Clerico R; Calvieri S
    Jpn J Clin Oncol; 2005 Sep; 35(9):507-13. PubMed ID: 16120623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma.
    Pyrhönen S; Hahka-Kemppinen M; Muhonen T; Nikkanen V; Eskelin S; Summanen P; Tarkkanen A; Kivelä T
    Cancer; 2002 Dec; 95(11):2366-72. PubMed ID: 12436444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma.
    McClay EF; McClay ME; Monroe L; Baron PL; Cole DJ; O'Brien PH; Metcalf JS; Maize JC
    Br J Cancer; 2000 Jul; 83(1):16-21. PubMed ID: 10883662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Chemotherapy of malignant melanoma].
    Ishihara K; Yamazaki N; Asano K
    Gan To Kagaku Ryoho; 1993 Aug; 20(10):1287-92. PubMed ID: 7688498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma.
    Lewis KD; Robinson WA; McCarter M; Pearlman N; O'Day SJ; Anderson C; Amatruda TT; Baron A; Zeng C; Becker M; Dollarhide S; Matijevich K; Gonzalez R
    J Clin Oncol; 2006 Jul; 24(19):3157-63. PubMed ID: 16809738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapeutic response of interferon-beta in malignant melanoma].
    Ishihara K
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):1010-6. PubMed ID: 2421645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Chemotherapy of malignant melanoma--current status].
    Karg C; Garbe C; Orfanos CE
    Hautarzt; 1990 Feb; 41(2):56-65. PubMed ID: 2180855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Adjuvant chemotherapy of malignant melanoma with DTIC. Lack of effect in stage I. Possible improvement of the prognosis for survival in stage IIb].
    Garbe C; Guenther-Eymann K; Stadler R; Orfanos CE
    Hautarzt; 1988 Apr; 39(4):205-12. PubMed ID: 3384660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Adjuvant chemotherapy as a component of complex treatment for skin melanoma].
    Kudriavtsev DV; Kudriavtseva GT; Mardynskiĭ IuS
    Vopr Onkol; 2008; 54(2):170-7. PubMed ID: 18522165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of therapy on the antioxidant status in patients with melanoma.
    Gadjeva V; Dimov A; Georgieva N
    J Clin Pharm Ther; 2008 Apr; 33(2):179-85. PubMed ID: 18315784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical trials of supplementary chemotherapy in cases of malignant melanoma of the skin with unfavorable prognosis after surgical treatment].
    Dobrek Z
    Wiad Lek; 1987 Feb; 40(4):237-41. PubMed ID: 3617746
    [No Abstract]   [Full Text] [Related]  

  • 16. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
    Hauschild A; Garbe C; Stolz W; Ellwanger U; Seiter S; Dummer R; Ugurel S; Sebastian G; Nashan D; Linse R; Achtelik W; Mohr P; Kaufmann R; Fey M; Ulrich J; Tilgen W
    Br J Cancer; 2001 Apr; 84(8):1036-42. PubMed ID: 11308250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Surgical treatment and regional chemotherapy in melanoma of the extremities].
    Henneking K; Binder J; Weyers W; Schwemmle K
    Chirurg; 1993 Feb; 64(2):134-8. PubMed ID: 8462350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Chemotherapy of malignant melanoma. Results of a controlled clinical trial comparing vincristine + dacarbazin (DTIC) with and without duborimycin (author's transl)].
    Chauvergne J; Clavel B; Klein T; Pommatau E
    Bull Cancer; 1978; 65(2):107-9. PubMed ID: 359067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of neoadjuvant biochemotherapy for stage III melanoma.
    Gibbs P; Anderson C; Pearlman N; LaClaire S; Becker M; Gatlin K; O'Driscoll M; Stephens J; Gonzalez R
    Cancer; 2002 Jan; 94(2):470-6. PubMed ID: 11900232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lomustine, vincristine, and procarbazine in the treatment of metastatic malignant melanoma.
    Shelley W; Quirt I; Bodurtha A; Iscoe N; Russell J; Paterson A; Young V
    Cancer Treat Rep; 1985 Sep; 69(9):941-4. PubMed ID: 2992784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.